However, integration of immunotherapies and immune checkpoint blockades targeting either the programmed cell death protein 1 (PD-1) or PD-L1 has been incorporated into routine clinical management of patients with NSCLC and has significantly improved patient outcomes (118–120). This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.